Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Ainsworth

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
International Journal of STD & AIDS|May 14, 2015
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reportsNadia Ahmed, Chinyere Okoli, Jonathan Ainsworth
BMJ Case Reports|June 28, 2012
The posterior reversible encephalopathy syndrome in HIV infectionSam Nightingale, Chris Wood, Jonathan Ainsworth
Lancet (London, England)|May 22, 2007
Global health and foreign policyChristopher Wood, Sally Hargreaves, Jonathan Ainsworth, et al.
The Journal of Infectious Diseases|January 6, 2007
Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapyMeghna Ramaswamy, Anele Waters, Colette Smith, et al.
AIDS (London, England)|September 9, 2014
High-level human herpesvirus-8 viremia and multicentric Castleman's disease following initiation of highly active antiretroviral therapySheila Lumley, Sara Madge, Diarmuid Nugent, et al.
The Journal of Antimicrobial Chemotherapy|December 17, 2011
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mgChinyere Okoli, Marco Siccardi, Sathish Thomas-William, et al.
Plos One|August 1, 2014
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairmentAlejandro Arenas-Pinto, Alan Winston, Wolfgang Stöhr, et al.
AIDS (London, England)|December 20, 2007
Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UKFiona M Burns, Anne M Johnson, James Nazroo, et al.
Plos One|April 13, 2011
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressorsCristina Cellerai, Alexandre Harari, Hans Stauss, et al.
The Journal of Infectious Diseases|July 29, 2009
Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi, Caroline Sabin, Richard Gilson, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
International Journal of STD & AIDS|May 14, 2015
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reportsNadia Ahmed, Chinyere Okoli, Jonathan Ainsworth
BMJ Case Reports|June 28, 2012
The posterior reversible encephalopathy syndrome in HIV infectionSam Nightingale, Chris Wood, Jonathan Ainsworth
Lancet (London, England)|May 22, 2007
Global health and foreign policyChristopher Wood, Sally Hargreaves, Jonathan Ainsworth, et al.
The Journal of Infectious Diseases|January 6, 2007
Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapyMeghna Ramaswamy, Anele Waters, Colette Smith, et al.
AIDS (London, England)|September 9, 2014
High-level human herpesvirus-8 viremia and multicentric Castleman's disease following initiation of highly active antiretroviral therapySheila Lumley, Sara Madge, Diarmuid Nugent, et al.
The Journal of Antimicrobial Chemotherapy|December 17, 2011
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mgChinyere Okoli, Marco Siccardi, Sathish Thomas-William, et al.
Plos One|August 1, 2014
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairmentAlejandro Arenas-Pinto, Alan Winston, Wolfgang Stöhr, et al.
AIDS (London, England)|December 20, 2007
Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UKFiona M Burns, Anne M Johnson, James Nazroo, et al.
Plos One|April 13, 2011
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressorsCristina Cellerai, Alexandre Harari, Hans Stauss, et al.
The Journal of Infectious Diseases|July 29, 2009
Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi, Caroline Sabin, Richard Gilson, et al.
Pageof 3